{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:17:26Z","timestamp":1784557046165,"version":"3.55.0"},"reference-count":12,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["edm.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"\n Summary<\/jats:title>\n Non-islet cell tumour hypoglycemia (NICTH), typically mediated by insulin-like growth factor 2 (IGF-2), is a rare but highly morbid paraneoplastic syndrome associated with tumours of mesenchymal or epithelial origin. Outside of dextrose administration and dietary modification which provide transient relief of hypoglycemia, resection of the underlying tumour is the only known cure for NICTH. Available medical therapies to manage hypoglycemia include glucocorticoids, recombinant growth hormone, and pasireotide. We report two cases of IGF-2 mediated hypoglycemia. The first was managed surgically to good effect, highlighting the importance of a timely diagnosis to maximise the likelihood of a surgical cure. The second patient had unresectable disease and was managed medically, adding to a growing number of cases supporting the efficacy of glucocorticoids and recombinant growth hormone in NICTH.<\/jats:p>\n <\/jats:sec>\n \n Learning points<\/jats:title>\n \n \n Recurrent fasting hypoglycemia in the setting of a malignancy should raise suspicion of non-islet cell tumour hypoglycemia (NICTH), which is typically mediated by IGF-2.<\/jats:p>\n <\/jats:list-item>\n \n The initial workup for NICTH should include a serum glucose, C-peptide, insulin, insulin antibodies, beta-hydroxybutyrate, IGF-2, IGF-1, and sulphonylurea screen during a spontaneous or induced hypoglycemic episode.<\/jats:p>\n <\/jats:list-item>\n \n An IGF-2\/IGF-1 ratio above 10 is highly suggestive of IGF-2-mediated hypoglycemia if the IGF-2 level is normal or elevated. False positives may be seen with sepsis and cachexia as both IGF-2 and IGF-1 are subnormal in these cases. A low IGF binding protein 3 (IGFBP3), such as in renal failure, may also result in a falsely normal or low IGF-2\/IGF-1 ratio.<\/jats:p>\n <\/jats:list-item>\n \n Surgical resection of the associated tumour is curative in most NICTH cases.<\/jats:p>\n <\/jats:list-item>\n \n When the tumour is unresectable, moderate-dose glucocorticoids, low-dose glucocorticoids in combination with recombinant growth hormone, and pasireotide are medical therapies with promising results in controlling NICTH.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:sec>","DOI":"10.1530\/edm-23-0089","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T07:17:58Z","timestamp":1709277478000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-2","source":"Crossref","is-referenced-by-count":4,"title":["IGF-2-mediated hypoglycemia: a case series and review of the medical therapies for refractory hypoglycemia"],"prefix":"10.1530","volume":"2024","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0892-3413","authenticated-orcid":true,"given":"Albert","family":"Vu","sequence":"first","affiliation":[{"name":"Division of Endocrinology & Metabolism, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Chik","sequence":"additional","affiliation":[{"name":"Division of Endocrinology & Metabolism, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kwong","sequence":"additional","affiliation":[{"name":"Division of Endocrinology & Metabolism, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"BMC Endocrine Disorders","first-page":"262","article-title":"IGF-2 mediated hypoglycemia and the paradox of an apparently benign lesion: a case report & review of the literature","volume":"22","author":"Crowley","year":"2022","unstructured":"Crowley MTLonergan EO'Callaghan PJoyce CMMorita MConlon N & O\u2019Halloran DJ. IGF-2 mediated hypoglycemia and the paradox of an apparently benign lesion: a case report & review of the literature. BMC Endocrine Disorders202222262. (https:\/\/doi.org\/10.1186\/s12902-022-01175-4)"},{"key":"bib2","series-title":"Medicine","first-page":"e7417","article-title":"Doege-Potter syndrome: a review of the literature including a new case report","volume":"96","author":"Han","year":"2017","unstructured":"Han GZhang ZShen XWang KZhao YHe JGao YShan XXin GLi C, et al.Doege-Potter syndrome: a review of the literature including a new case report. Medicine201796e7417. (https:\/\/doi.org\/10.1097\/MD.0000000000007417)"},{"key":"bib3","series-title":"Endocrine Reviews","first-page":"798","article-title":"Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive","volume":"34","author":"Dynkevich","year":"2013","unstructured":"Dynkevich YRother KIWhitford IQureshi SGaliveeti SSzulc ALDanoff ABreen TLKaviani NShanik MH, et al.Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive. Endocrine Reviews201334798\u2013826. (https:\/\/doi.org\/10.1210\/er.2012-1033)"},{"key":"bib4","series-title":"Endocrine Reviews","first-page":"379","article-title":"Insulin receptor isoforms in physiology and disease: an updated view","volume":"38","author":"Belfiore","year":"2017","unstructured":"Belfiore AMalaguarnera RVella VLawrence MCSciacca LFrasca FMorrione A & Vigneri R. Insulin receptor isoforms in physiology and disease: an updated view. Endocrine Reviews201738379\u2013431. (https:\/\/doi.org\/10.1210\/er.2017-00073)"},{"key":"bib5","series-title":"Growth Hormone and IGF Research","first-page":"211","article-title":"Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia","volume":"16","author":"Fukuda","year":"2006","unstructured":"Fukuda IHizuka NIshikawa YYasumoto KMurakami YSata AMorita JKurimoto MOkubo Y & Takano K. Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Hormone and IGF Research200616211\u2013216. (https:\/\/doi.org\/10.1016\/j.ghir.2006.05.003)"},{"key":"bib6","series-title":"Growth Hormone and IGF Research","first-page":"8","article-title":"The current status of IGF-I assays--a 2009 update","volume":"20","author":"Frystyk","year":"2010","unstructured":"Frystyk JFreda P & Clemmons DR. The current status of IGF-I assays--a 2009 update. Growth Hormone and IGF Research2010208\u201318. (https:\/\/doi.org\/10.1016\/j.ghir.2009.09.004)"},{"key":"bib7","series-title":"International Journal of Clinical Oncology","first-page":"478","article-title":"The therapeutic challenge of a nonresectable solitary fibrous tumor in a hypoglycemic patient","volume":"11","author":"de Boer","year":"2006","unstructured":"de Boer JJager PLWiggers TNieboer PMachteld Wymenga ANPras EHoogenberg KSleijfer DTSuurmeijer AJ & van der Graaf WT. The therapeutic challenge of a nonresectable solitary fibrous tumor in a hypoglycemic patient. International Journal of Clinical Oncology200611478\u2013481. (https:\/\/doi.org\/10.1007\/s10147-006-0606-1)"},{"key":"bib8","series-title":"Oncology Letters","first-page":"898","article-title":"Refractory hypoglycemia controlled by systemic chemotherapy with advanced hepatocellular carcinoma: a case report","volume":"11","author":"Huang","year":"2016","unstructured":"Huang JS & Chang PH. Refractory hypoglycemia controlled by systemic chemotherapy with advanced hepatocellular carcinoma: a case report. Oncology Letters201611898\u2013900. (https:\/\/doi.org\/10.3892\/ol.2015.3915)"},{"key":"bib9","series-title":"Clinical Endocrinology","first-page":"457","article-title":"The effectiveness of different treatment options for non-islet cell tumour hypoglycaemia","volume":"60","author":"Teale","year":"2004","unstructured":"Teale JD & Wark G. The effectiveness of different treatment options for non-islet cell tumour hypoglycaemia. Clinical Endocrinology200460457\u2013460. (https:\/\/doi.org\/10.1111\/j.1365-2265.2004.01989.x)"},{"key":"bib10","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"2700","article-title":"Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hormone in nonislet cell tumor hypoglycemia","volume":"80","author":"Baxter","year":"1995","unstructured":"Baxter RCHolman SRCorbould AStranks SHo PJ & Braund W. Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hormone in nonislet cell tumor hypoglycemia. Journal of Clinical Endocrinology and Metabolism1995802700\u20132708. (https:\/\/doi.org\/10.1210\/jcem.80.9.7545698)"},{"key":"bib11","series-title":"Clinical Therapeutics","first-page":"246","article-title":"Treatment of hypoglycemia using combined glucocorticoid and recombinant human growth hormone in a patient with a metastatic non-islet cell tumor hypoglycemia","volume":"27","author":"Bourcigaux","year":"2005","unstructured":"Bourcigaux NArnault-Ouary GChristol RP\u00e9rin LCharbonnel B & Le Bouc Y. Treatment of hypoglycemia using combined glucocorticoid and recombinant human growth hormone in a patient with a metastatic non-islet cell tumor hypoglycemia. Clinical Therapeutics200527246\u2013251. (https:\/\/doi.org\/10.1016\/j.clinthera.2005.02.004)"},{"key":"bib12","series-title":"Journal of the Endocrine Society","first-page":"bvaa171","article-title":"Pasireotide: a novel treatment for tumor-induced hypoglycemia due to insulinoma and non-islet cell tumor hypoglycemia","volume":"5","author":"Siddiqui","year":"2021","unstructured":"Siddiqui MVora AAli SAbramowitz J & Mirfakhraee S. Pasireotide: a novel treatment for tumor-induced hypoglycemia due to insulinoma and non-islet cell tumor hypoglycemia. Journal of the Endocrine Society20215bvaa171. (https:\/\/doi.org\/10.1210\/jendso\/bvaa171)"}],"container-title":["Endocrinology, Diabetes & Metabolism Case Reports"],"original-title":[],"link":[{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2024\/1\/EDM23-0089.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2024\/1\/EDM23-0089.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2024\/1\/EDM23-0089.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:48:17Z","timestamp":1784555297000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/edm\/article\/3692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":12,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/edm-23-0089","relation":{},"ISSN":["2052-0573"],"issn-type":[{"value":"2052-0573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,1]]}}}